Biomarkers and prognosis in malignant lymphomas

Clinical Lymphoma and Myeloma

Volumn 9, Issue 2, 2009, Pages 160-166

  Hagenbeek, Anton ^a   Gascoyne, Randy ^b   Dreyling, Martin ^c   Kluin, Philip ^d   Engert, Andreas ^e   Salles, Gilles ^f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Burkitt lymphoma; Chromosomal translocation; Diffuse large B cell lymphoma; Follicular non Hodgkin lymphoma; Hodgkin lymphoma; Mantle cell; Tissue microarrays

Indexed keywords

BIM PROTEIN; BIOLOGICAL MARKER; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISONE; PROCARBAZINE; PROTEIN NOXA; RITUXIMAB; TOLL LIKE RECEPTOR 9; VINCRISTINE; TUMOR MARKER;

ARTICLE; BURKITT LYMPHOMA; CANCER DIAGNOSIS; CHROMOSOME ABERRATION; DIFFUSE LARGE B CELL LYMPHOMA; DNA DAMAGE; DNA REPAIR; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CONFERENCE PAPER;

HUMANS; LYMPHOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650678446     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.038     Document Type: Article

References (31)

1. Roulland S, Navarro JM, Grenot P, et al. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J Exp Med 2006; 203:2425-31.
2. De Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23:6358-63.
3. Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007; 109:5439-46.
4. Ross CW, Ouillette PD, Saddler CM, et al. Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res 2007; 13:4777-85.
5. Ruminy P, Jardin F, Picquenot JM, et al. S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: Early direct or late from FL progenitor cells. Blood 2008; 112:1951-9.
6. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106:2169-74.
7. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7:750-62.
8. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3:185-97.
9. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2008; 111:558-65.
10. European MCL Network [Web site]. Available at: www.european-mcl.net
11. Weigert O, Unterhalt M, Hiddemann W, et al. Current management of mantle cell lymphoma. Drugs 2007; 67:1689-702.
12. Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106:1031-6.
13. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354:2431-42.
14. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419-30.
15. Lin P, Medeiros LJ. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica 2007; 92:1297-301.
16. Klapper W, Szczepanowski M, Burkhardt B, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood 2008; 112:1374-81.
17. K̈ppers R, Rajewksy K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16:471-93.
18. K̈ppers R, Klein U, Schwering I, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003; 111:529-37.
19. Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma. An analysis from the German Hodgkin Study Group. J Clin Oncol 2005; 23:8003-11.
20. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-14.
21. Klein U, Dalla Favera R. Germinal centers: role in B-cell physiology and malignancy. Nat Rev Immunol 2008; 8:22-33.
22. Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal centerderived lymphomagenesis. Nat Genet 2008; 40:108-12.
23. Saito M, Gao J, Basso K, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007; 12:280-92.
24. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319:1676-9.
25. Nielander I, Bug S, Richter J, et al. Combining array-based approaches for the identification of candidate tumor suppressor loci in mature lymphoid neoplasms. APMIS 2007; 115:1107-34.
26. De Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications. A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25:805-12.
27. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008; 26:447-54.
28. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma treated with R-CHOP. Blood 2008; 112:3425-33.
29. Jais JP, Haioun C, Molina TJ, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22:1917-24.
30. Mounier N, Briere J, Gisselbrecht C, et al. Groupe d'Etude des Lymphomes de l'Adulte. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 2006; 91:715-6.
31. Lunenburg Lymphoma Biomarker Consortium (LLBC). First results of an international study to etstablish a new clinico-biological prognostic index for diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2008;19 (suppl 4):Abstract 054bis.